CDT Equity Inc. (CDT)Stock Price & Financial Statements
AboutCDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.Show more
- Revenue $0
- EBITDA -$15M -590.1%
- Net Income -$18M -3227.5%
- EPS (Diluted) -20.53 -470.3%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE -
- ROIC -
- Debt/Equity -
- Interest Coverage -10.24 +58.9%
Key Insights
Based on financial data analysisStrengths
No significant strengths identified
Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 21.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-48.91%
EPS CAGR
10Y-
5Y-
3Y-
TTM-3880.43%
ROCE
10Y Avg-8114.65%
5Y Avg-8114.65%
3Y Avg-840.58%
Latest-
Peer Comparison
Royalty and IP Monetization Vehicles| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 BTXBlackRock Technology and Private Equity Term Trust | 772.62M | 6.62 | 38.94 | -81.13% | 87.75% | 1.87% | 35.88% | |
 RPRXRoyalty Pharma plc | 26.77B | 47.43 | 26.65 | 5.06% | 32.55% | 7.95% | 9.3% | 0.91 |
 INVAInnoviva, Inc. | 1.7B | 22.73 | 6.89 | 18.52% | 65.38% | 23.12% | 11.54% | |
CDTCDT Equity Inc. | 1.46M | 0.71 | -0.03 | -474.64% | ||||
 CBUSCibus, Inc. | 98.77M | 3.33 | -0.31 | 134.56% | -31.34% | -228.53% | 0.37 | |
 XOMAPXOMA Corporation | 317.24M | 25.77 | -15.62 | 498.72% | 46.15% | 20.14% | 1.46 | |
 XOMAXOMA Royalty Corp. | 316.14M | 26.45 | -16.03 | 498.72% | 41.06% | 17.91% | 1.46 | |
 LGNDLigand Pharmaceuticals Incorporated | 4.11B | 208.95 | -949.77 | 27.28% | 19.34% | 5.11% | 1.88% | 0.01 |
Compare CDT vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 457K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | -457K |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 3.17M | 3.16M | 5.26M | 14.96M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 2.89M | 3.05M | 5.17M | 11.58M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 283K | 111K | 90K | 3.38M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -3.17M | -3.16M | -5.26M | -15.42M |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | 0.41% | -66.52% | -193.03% |
| EBITDA | -3.17M | -4.89M | 3.05M | -14.96M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -54.02% | 162.47% | -590.08% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 457K |
| EBIT | -3.17M | -4.89M | 3.05M | -16.3M |
| Net Interest Income | 0 | 1.98M | -196K | -1.49M |
| Interest Income | 0 | 1.98M | 15K | 13K |
| Interest Expense | 0 | 0 | 211K | 1.51M |
| Other Income/Expense | -484K | -1.73M | 8.1M | -2.38M |
| Pretax Income | -3.66M | -4.89M | 2.84M | -17.8M |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | -18.82% | 100% |
| Net Income | -3.66M | -4.89M | -535K | -17.8M |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -33.63% | 89.05% | -3227.48% |
| Net Income (Continuing) | -3.66M | -4.89M | 2.84M | -17.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.01 | -0.07 | -3.60 | -20.53 |
| EPS Growth % | - | 93.32% | -5233.33% | -470.28% |
| EPS (Basic) | -1.01 | -0.07 | -3.60 | -20.53 |
| Diluted Shares Outstanding | 576 | 3.62M | 1.7M | 2.06M |
| Basic Shares Outstanding | 576 | 3.62M | 1.67M | 2.03M |
| Dividend Payout Ratio | - | - | - | - |
Balance Sheet
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 104.16K | 0 | 5.73M | 2.71M |
| Cash & Short-Term Investments | 48.55K | 0 | 4.23M | 554K |
| Cash Only | 48.55K | 0 | 4.23M | 554K |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 489K |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 108.96K | 5K | 1.49M | 1.48M |
| Property, Plant & Equipment | 0 | 0 | 0 | 303K |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 1.02B |
| Intangible Assets | 0 | 5K | 0 | 419.07M |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 108.96K | 0 | 1.49M | -1.44B |
| Total Assets | 213.13K | 5K | 7.22M | 4.19M |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | -97.65% | 144380% | -41.96% |
| Total Current Liabilities | 192.51K | 4.18M | 1.8M | 10.74M |
| Accounts Payable | 0 | 0 | 215K | 1.43M |
| Days Payables Outstanding | - | - | - | 1.14K |
| Short-Term Debt | 177.06K | 175K | 985K | 7.35M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.45K | 3.29M | 0 | 0 |
| Current Ratio | 0.54x | - | 3.18x | 0.25x |
| Quick Ratio | 0.54x | - | 3.18x | 0.25x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 0 | 5.92M | 5.88M | 245K |
| Long-Term Debt | 0 | 1.83M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 107K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | -545.75K | 5.88M | 138K |
| Total Liabilities | 192.51K | 10.09M | 7.68M | 10.99M |
| Total Debt | 177.06K | 2.01M | 985K | 7.46M |
| Net Debt | 128.5K | 2.01M | -3.24M | 6.9M |
| Debt / Equity | 8.59x | - | - | - |
| Debt / EBITDA | - | - | 0.32x | - |
| Net Debt / EBITDA | - | - | -1.06x | - |
| Interest Coverage | - | - | -24.94x | -10.24x |
| Total Equity | 20.62K | -10.09M | -457K | -6.79M |
| Equity Growth % | - | -49030.6% | 95.47% | -1386.43% |
| Book Value per Share | 35.79 | -2.79 | -0.27 | -3.29 |
| Total Shareholders' Equity | 20.62K | -10.09M | -457K | -6.79M |
| Common Stock | 331 | 6K | 7K | 14K |
| Retained Earnings | -4.38K | -10.77M | -11.3M | -29.1M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 675K | 411K | 414K |
| Minority Interest | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -2.15M | -2.27M | -7.72M | -9.68M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -5.35% | -240.91% | -25.33% |
| Net Income | -3.66M | -4.89M | -535K | -17.8M |
| Depreciation & Amortization | 0 | 0 | 0 | 457K |
| Stock-Based Compensation | 0 | 0 | 199K | 1.63M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 149K | 2.02M | -4.87M | 6.17M |
| Working Capital Changes | 1.36M | 596K | -2.52M | -142K |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 215K | 1.23M |
| Cash from Investing | 0 | -183K | 725K | -43K |
| Capital Expenditures | 0 | 0 | 0 | -51K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | -331K | 228K | 0 |
| Cash from Financing | 1.9M | 2.45M | 10.93M | 6.07M |
| Debt Issued (Net) | 688K | 1.11M | 2.29M | 2.45M |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 8.64M | 289K |
| Net Change in Cash | -252K | 0 | 4.23M | -3.67M |
| Free Cash Flow | -2.15M | -2.27M | -7.72M | -9.73M |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -5.35% | -240.91% | -25.99% |
| FCF per Share | -3733.40 | -0.63 | -4.55 | -4.71 |
| FCF Conversion (FCF/Net Income) | 0.59x | 0.46x | 14.44x | 0.54x |
| Interest Paid | 0 | 0 | 124K | 80K |
| Taxes Paid | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | -17736.07% | - | - | - |
| Debt / Equity | 8.59x | - | - | - |
| Interest Coverage | - | - | -24.94x | -10.24x |
| FCF Conversion | 0.59x | 0.46x | 14.44x | 0.54x |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics